Cabaletta Bio, Inc. (CABA) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Debt-Equity Ratio (DER) CABA equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth CABA has never had growing revenue.
Net Income Growth CABA has never had growing net income.
Price to Book (PBV) Ratio Overvalued price-to-book. CABA stock price is overvalued by more than 2x the price-to-book value.
Net Income CABA never has positive net income for 2 years.
Dividend Yield CABA has low dividend yield (0%).
Return of Assets CABA has low return of asset (-55.82%).
Return of Equity CABA has low return of equity (-50.4%).
Revenue CABA never has positive revenue for 2 years.
Return of Invested Capital CABA has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

0 USD

Dividend

Financial Ratios

CEO

CEO Name

Dr. Steven Nichtberger

Management

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Additional Information

Company name

Cabaletta Bio, Inc.

Symbol

NASDAQ:CABA

Exchange

NASDAQ Global Select

Industry

Biotechnology

Sector

Healthcare

Address

2929 Arch St Ste 600
Philadelphia
PENNSYLVANIA
US
19104

Website

https://www.cabalettabio.com